Science Current Events | Science News |

Research shows how 'Mallard' dye fills need for speed

February 15, 2013
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.

Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood.

Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.

In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.

The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.

Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.

Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.

"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."

The York researchers worked with a team led by Sabrina Pricl at the University of Trieste who used high-level computer modelling to understand precisely how Mallard Blue binds to heparin so strongly.

The next stage in this research would involve the incorporation of this new dye into a device for simple bedside read-out of heparin levels in blood.

University of York

Related Heparin Current Events and Heparin News Articles

Low stent thrombosis rates with primary PCI, regardless of antithrombotic choice
Stent thrombosis following urgent angioplasty for acute heart attack occurred in less than 1% of patients in a large, "real-world" registry, regardless of whether the antithrombotic treatment used during the procedure was bivalirudin, heparin alone, or a GP IIb/IIIa inhibitor (typically in combination with heparin).

New studies examine the significant risk of blood clots in post-surgical lung cancer patients
One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called pulmonary embolism - PE) or in the legs (also known as deep vein thrombosis - DVT).

Revised guidelines on reducing risk, treatment options for thromboembolic disease in pregnancy
Advice on preventing and treating venous thromboembolism (VTE) during pregnancy, birth and following delivery is outlined in two new revised guidelines published today (13 April) by the Royal College of Obstetricians and Gynaecologists (RCOG) and launched at the RCOG World Congress in Brisbane, Australia.

Common drug is re-engineered to improve surgery outcomes
A Northwestern University research team potentially has found a safer way to keep blood vessels healthy during and after surgery.

Serious risks from common IV devices mean doctors should choose carefully, U-M experts say
Every day, patients around the country get IV devices placed in their arms, to make it easier to receive medicines or have blood drawn over the course of days or weeks. But these PICC lines, as they're called, also raise the risk of potentially dangerous blood clots.

Trial of bivalirudin during angioplasty reports mixed results
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy.

ASH report: 'Systems-based' hematologist is new way to provide hematology expertise
A report, released today from the American Society of Hematology (ASH) in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today's rapidly changing U.S. health-care system.

Platelet transfusions increase odds of death in some rare blood cell disorders
People hospitalized with certain rare blood cell disorders frequently receive a treatment that is associated with a two- to fivefold increase in death, according to a new study that reviewed hospital records nationwide.

Apixaban in deep vein thrombosis and pulmonary embolism: patients with high BMI benefit considerably
Apixaban (trade name Eliquis) has been approved since July 2014 for acute treatment of adults with deep vein thrombosis or pulmonary embolism.

Combined strategies help patients with adverse heparin reaction before heart surgery
New evidence suggests that therapeutic plasma exchange and appropriate blood testing could help patients who are in urgent need of heart surgery, but have a history of an adverse reaction to the blood thinner heparin.
More Heparin Current Events and Heparin News Articles

Heparin-Induced Thrombocytopenia, Fifth Edition (Fundamental and Clinical Cardiology)

Heparin-Induced Thrombocytopenia, Fifth Edition (Fundamental and Clinical Cardiology)
by Theodore E. Warkentin (Editor), Andreas Greinacher (Editor)

Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most frequent and devastating adverse drug reactions encountered by physicians. This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of this condition. Identifying key signs and symptoms and providing clear intervention strategies—including the use of alternative anticoagulants to manage critical circumstances—this is an essential resource for all clinicians and a "must" for hematology consultants. Heparin-Induced Thrombocytopenia, Fifth Edition explores: Clinical and laboratory studies on HIT The immune basis and pathogenesis, animal models, and laboratory testing for HIT...




Target audience: Medical students, residents, healthcare workers, patients
Weekly updates? Yes
Multiple choice questions? Yes
Board review? Yes

Heparin-Binding Proteins

Heparin-Binding Proteins
by H. Edward Conrad (Author)

This book describes the complex structures of heparins and heparan sulfates (heparinoids) and how they are generated by their biosynthetic pathways. The book also details the methodologies for studying these structures and their cellular metabolism. Heparin-Binding Proteins introduces the general nature of interactions between heparinoids and proteins, and presents the role for these structures in their interactions with the proteins of the hemostatic mechanisms, fibroblasts growth factors, superoxide dismutase, and lipoproteins.

Key Features
* Covers cellular metabolism of heparinoid proteoglycans
* Written by a distinguished expert in the field of carbohydrate biochemistry
* Describes the roles of heparan sulfate proteoglycans...

  Chemistry and Biology of Heparin: International Conference Proceedings (Developments in biochemistry)
by Roger L. Lundblad (Editor), etc. (Editor)

Heparin - A Century of Progress: 207 (Handbook of Experimental Pharmacology)

Heparin - A Century of Progress: 207 (Handbook of Experimental Pharmacology)
by Springer

Heparins remain amongst the most commonly used drugs in clinical practice.  Almost 100 years have passed since the initial discovery of this complex substance and, during this time, understanding of the nature and uses of heparin and related molecules has grown dramatically. The aim of this volume is to summarise the developments that have led to the current status of both heparins as drugs and the field of heparin research, with a focus on the particularly rapid progress that has been made over the past three decades. Individual sections are dedicated to the nature of heparin as a biological molecule, the current approaches and techniques that are used to ensure the safety and reliability of heparin as a medicine, the clinical pharmacology of heparin as an anticoagulant drug, effects...

Heparin-Induced Thrombocytopenia, Fourth Edition (Fundamental and Clinical Cardiology)

Heparin-Induced Thrombocytopenia, Fourth Edition (Fundamental and Clinical Cardiology)
by CRC Press

Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most potentially devastating and frequent adverse drug reactions encountered by physicians. This Fourth Edition reinforces its standing as the leading guide to the accurate diagnosis and management of HIT by identifying key signs and symptoms of this disorder and providing clear intervention strategies, including detailed information on the use of alternative anticoagulants to manage these critical circumstances.

Intended for those requiring an expert source of guidance for the quick detection and control of HIT, this reference:

contains new chapters on novel pharmacotherapies, recent drug approvals, current dosing guidelines, and the advantages and...

Chemistry and Biology of Heparin and Heparan Sulfate

Chemistry and Biology of Heparin and Heparan Sulfate
by Hari G. Garg (Editor), Robert J. Linhardt (Editor), Charles A. Hales (Editor)

The chemistry, biochemistry and pharmacology of heparin and heparan sulfate have been and continue to be a major scientific undertaking - heparin and its derivative remain important drugs in clinical practice. Chemistry and Biology of Heparin and Heparan Sulfate provides readers with an insight into the chemistry, biology and clinical applications of heparin and heparan sulfate and examines their function in various physiological and pathological conditions. Providing a wealth of useful information, no other tome covers the diversity of topics in the field. Students, doctors, chemists, biochemists, and research scientists will find this book an invaluable source for updating their current knowledge of developments in this area.


Mysterious Heparin, the Key to Open Heart Surgery

Mysterious Heparin, the Key to Open Heart Surgery
by W.C. Bigelow (Author)

One of the world's pioneering heart surgeons, Canada's W.G. Bigelow, explains the mysterious anticoagulant heparin, essential to open heart surgery, from its discovery at Johns Hopkins University in 1916 through its purification for human use, finally supplying the key that makes possible the definitive treatment of the most common cause of illness and death -- heart disease.

Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence

Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence
by Monique Sarret (Author), Andre Kher (Author), Francis Toulemonde (Author)

Each section is followed with expert commentary and a critical evaluation of the studies under consideration!
This reference, unique in format, gathers the most relevant clinical studies, reviews the different biochemical properties, and assesses the therapeutic efficacy of low molecular weight heparins (LMWHs) from 1985 to the present.
Presents each study on two pages-the first describes the main parameters of the study, including experimental conditions, location, number of patients, medications, surgical procedures, and anesthesia type, and the second provides a table of results based on the study's data!
With contributions from 35 leading international physicians, Low Molecular Weight Heparin Therapy
recommends treatment practices based on levels of evidence attained in...

Heparin: Structure, Drug Delivery Applications and Clinical Outcomes (Pharmacology-Research, Safety Testing and Regulations)

Heparin: Structure, Drug Delivery Applications and Clinical Outcomes (Pharmacology-Research, Safety Testing and Regulations)
by Nicole B. Wilkinson (Editor)

© 2015